Nivolumab in combination with ipilimumab as first-line treatment of patients with NSCLC continues to show an improved overall survival

| Jun 2020 | ASCO20 Virtual |

A three-year update from the CheckMate-227 trial was presented by Suresh S. Ramalingam, M.D. and professor of hematology and medical oncology, in an oral poster session at this year's ASCO20 Virutal Scientific program. The results of the CheckMate-227 study showed that novolumab in compilation with ipilimumab for NSCLC continued to show durable and long-term efficacy benefits, including a significant overall survival rate, compared to chemo alone - regardless of the PD-L1 expression. Thus, the study challenges the current indications. The overall survival (OS) rate was 33% after a median of 43,1 months of treatment for the combination therapy, compared to 22% in the chemo-treated group with PD-L1 expression higher than 1%. The median OS was 17,1 months for the nivolumab-ipilumab group, compared with 14,9 months for the chemo-treated group (hazard Ratio (HR): 0.79; 95%, confidence interval (CI): 0.67,). For patients with PD-L1 expression lower than 1%, PFS was 13% for nivolumab-ipilumab patients compared to 2% for chemotherapy. The hazard ratio for PFS was 0.75 for nivolumab-ipilumab vs chemotherapy. After three years, the group of patients on nivolumab-ipilumab treatment achieved a PFS of 18% compared with 4% in the placebo group. 38% of patients had continued response three years after starting the treatment. For patients in the chemotherapy group, 4% had a response after three years. Patients with PD-L1 expression <1%, achieved an OS rate of 34% after three years of nivolumap therapy in combination with ipilumab, compared to 15% for chemotherapy patients (HR: 0.64; 95% CI: 0.51 to 0.81 ). In addition, 13% of patients were alive in the nivolumab-ipilumab group after three years compared to 2% in the chemotherapy group three after randomization. Of patients with response, 34% had continued response in the nivolumab-ipilumab group compared with 0% in the control group for patients with PD-L1 expression <1%. Read the English abstract published on Asco here.